Earnings Call · Q2 FY2023·2023-08-03

Q2 23EPS -5.26%·Rev n/aQ1 23EPS +15.22%·Rev n/aQ4 22EPS -0.72%·Rev n/aQ3 22EPS -19.20%·Rev n/a⚠ consensus missing

Intellia Therapeutics, Inc. NTLA

Ian Karp — Head of Investor Relations

John Leonard — Chief Executive Officer

David Lebwohl — Chief Medical Officer

Laura Sepp-Lorenzino — Chief Scientific Officer

Glenn Goddard — Chief Financial Officer

−1.6%1d on move date−1.3% vs SPY3d−1.7%5d+0.8%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more NTLA calls or request research access.

More NTLA calls Browse calls Request research access